Top Health Tech Companies in San Francisco Bay Area, CA (961)

Market Expansion: Operations span all 50 states and Washington, D.C., with coverage reported across 100+ health plans and expansion into Medicare Advantage and Medicaid. This broadened payer and geographic footprint increases addressable demand and distribution leverage.

Product Line Growth: Offerings have expanded beyond matching into EHR, AI‑assisted notes, telehealth, billing, integrated‑care referrals, and a patient app. These additions deepen provider engagement and create more touchpoints for utilization and scale.

Strong Revenue Growth: Annual revenue is described as having more than doubled over a recent 12‑month period in 2024, indicating accelerating commercial momentum. While later‑period figures are not disclosed, the earlier surge aligns with rapid operating scale increases.

Strong Revenue Growth: Revenue is rising across 2025 and into 2026, with Galleri driving year-over-year increases and volumes outpacing revenue. Feedback suggests growth accelerated in early 2026 as test adoption broadened.

Strategic Partnerships: Partnerships such as Epic EHR integration and a collaboration with Samsung for Asia expansion are expanding distribution and market access. These relationships also support commercialization through employers, health systems and digital-health channels.

Investor Backing & Capital Strength: A sizable cash balance and recent equity financing provide a substantial runway to fund R&D and commercial expansion. This capital position helps buffer the costs of scaling while regulatory review proceeds.

Healthy Cash Flow: Free cash flow reached $317.5M in FY2026, up 19% year over year, underscoring strong cash generation. Operating cash flow also increased 19% to $326.5M, indicating robust cash conversion.

Profitability: Operating profitability expanded in FY2026, with adjusted EBITDA rising 14% to $357.8M. This points to solid earnings power alongside multi‑year revenue growth.

Strong Market Position & Advantage: Platform reach includes more than 85% of U.S. physicians, and workflow‑active prescribers grew 30%+ year over year. AI Search queries also rose more than 25% quarter over quarter, evidencing deepening engagement.

Strong Revenue Growth: Revenue is described as rising rapidly, surpassing $750 million in 2025 with 45% year-over-year growth, alongside expanding customer reach. The multi-year trend from roughly $400 million in 2023 to $750 million-plus in 2025 points to sustained expansion across the core business.

Profitability: Profitability is reported for eight consecutive years through 2025, with adjusted EBITDA margin improving by five percentage points in 2025. This indicates expansion has been achieved without relying on sustained operating losses.

Diversified Revenue Streams: Growth extends beyond the registry into healthcare, media, retail, and financial services, with Health up 64% and Media up 35% year over year in 2025. Physical showrooms and fulfillment investments further support multiple avenues for monetization.

Investor Backing & Capital Strength: The $31 million Series A led by Oak HC/FT with participation from Norwest, Y Combinator, and others provides resources for deployment, hiring, and AI product development. Feedback suggests this capital has strengthened the company’s ability to scale operations across health systems.

Market Expansion: Deployments span dozens of hospitals, with more than 15 health systems reportedly under multi-year, enterprise-wide contracts and named customers such as MemorialCare, Allina Health, Northwestern Medicine, and others. Feedback suggests the platform manages millions of shifts weekly, indicating meaningful operational footprint.

Product Line Growth: The company is extending beyond staffing and scheduling into patient throughput and capacity optimization, with stated plans to invest Series A capital into AI model development. Feedback suggests this broadened scope positions the platform to address a wider set of hospital operations.

Strong Revenue Growth: Feedback suggests AKASA reports more than tenfold growth since mid-2024 and nearly sixfold year-over-year inpatient volume processed, indicating rapid commercial traction and usage expansion.

Market Expansion: Feedback suggests deployments have broadened across major U.S. health systems, with a footprint reportedly spanning roughly 500 hospitals and customers representing about 10% of U.S. inpatient discharges.

Investor Backing & Capital Strength: Feedback suggests AKASA has attracted substantial capital, with reported total funding around $200M+, providing resources to scale products and partnerships.

Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.

Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.

Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.

Strong Hiring & Retention: Headcount and hiring momentum are evident, with third-party estimates showing growth from roughly the mid‑teens of thousands in 2024 to 20,000+ by 2025–2026 and plans to hire thousands, alongside new capacity such as the Hyderabad operations center. This suggests the company is scaling delivery and talent depth across geographies.

Innovation-Driven Growth: The firm has expanded into AI and digital offerings, including its ZAIDYN platform, acquisitions like Digital Additive and Torrent Consulting, and launches such as Myelo developed with the International Myeloma Foundation. These moves indicate investment beyond traditional consulting into scalable, tech‑enabled services.

Market Expansion: A dedicated mid‑cap pharmaceutical vertical and the opening of an operations center in Hyderabad point to deliberate expansion in target segments and delivery footprint. These steps signal efforts to broaden served markets and strengthen execution capacity.

Strong Revenue Growth: Reported ARR surpassed $200 million in June 2026 with five consecutive years of 100% year-over-year growth, indicating rapid scaling. Adoption breadth, including claims of powering one in six U.S. apartments, reinforces the commercial momentum behind that trajectory.

Investor Backing & Capital Strength: A $350 million round in September 2026 at a $4 billion valuation, with major existing investors participating alongside Ontario Teachers’ Pension Plan, underscores substantial access to capital. This financing signals strong confidence to fund continued product development and go-to-market expansion.

Market Expansion: Reach reportedly grew from about one in twelve U.S. apartments in 2024 to one in six in 2026, alongside plans for a second engineering hub in San Francisco. The company is also expanding from leasing into broader property-management workflows and healthcare administration.

Strong Revenue Growth: Feedback suggests revenue expanded rapidly, highlighted by a first-place ranking in the FT’s 2026 Americas’ Fastest-Growing Companies based on 2021–2024 growth and a reported $617.4M in 2024 revenue. Additional signals include reported surges in appointments and broader commercial activity across 2025–2026.

Investor Backing & Capital Strength: Feedback suggests substantial access to capital, including a $150M Series D in March 2026 and cumulative funding of about $328M. This capital appears to support expansion into insurers, employers, and health-system partnerships.

Market Expansion: Feedback suggests the company expanded distribution via 125+ health-plan partners (later 135), employer benefits, and health-system integrations. These channels appear to broaden reach beyond direct patient acquisition.

Strong Revenue Growth: A sixfold year-over-year revenue increase was reported in May 2025, indicating rapid commercial momentum. Rising visit volumes from roughly 5,000 in 2022 to 125,000+ in 2025 further reinforce this trajectory.

Market Expansion: Operations expanded from five states in 2023 to 18 by May 2025 and to nearly 25 states by February 2026. Coverage increasingly spans Medicare, Medicaid, and Marketplace populations, widening the addressable market.

Investor Backing & Capital Strength: A $55 million Series B in May 2025 brought total funding above $125 million, led by prominent investors. This capital base supports ongoing technology, staffing, and multistate rollout.

Strong Revenue Growth: Recent financial results highlight sustained top-line expansion with rising quarterly revenue and management increasing full‑year guidance, indicating momentum across 2025 and into 2026.

Diversified Revenue Streams: Growth is coming from both diagnostics and data licensing/AI applications, with testing volumes and data contracts expanding rather than reliance on a single line of business.

Customer Loyalty & Retention: Reported net revenue retention above 100% and sizable remaining contract value suggest existing pharmaceutical customers are deepening engagements.

Strong Revenue Growth: Evidence points to ARR reaching about $210M with continued year-over-year increases, and company statements indicate surpassing $200M in annualized revenue. Feedback suggests upselling and higher average revenue per customer support expansion from existing accounts.

Market Expansion: Adoption reportedly grew from ~410 customers in 2020 to 1,200+ by 2024, with 240 new customers added in 2024 and penetration into top-50 global biopharma firms. Feedback suggests partnerships and geographic breadth bolster reach across biotech and pharma.

Innovation-Driven Growth: Product launches in AI, automation, and broader R&D workflows, plus acquisitions and collaborations (e.g., Lilly TuneLab, NVIDIA) indicate active investment in next-generation capabilities. Feedback suggests these moves expand use cases and deepen platform integration in labs.